Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated October 09, 2020, titled "No significant clinical benefit with Umifenovir addition in COVID-19treatment: Glenmark clinical study".
Press Release Oct 09 2020
Filed with NSE ·
6ix hasn’t read this filing yet.
Glenmark Pharmaceuticals Limited on 6ix
Earlier from Glenmark Pharmaceuticals
Later from Glenmark Pharmaceuticals
- Press Release Oct 14 2020
- Press Release Oct 19 2020
- Press Release Nov 11 2020
- Press Release Nov 23 2020
- Press Release Nov 26 2020
Follow Glenmark Pharmaceuticals into a list and get an email when it puts out news.
Follow Glenmark Pharmaceuticals